Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox.

[1]  A. Ganser,et al.  Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. , 2010, Leukemia research.

[2]  A. Stamatoullas,et al.  Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). , 2010, Leukemia research.

[3]  G. Bruin,et al.  Pharmacokinetics, Metabolism, and Disposition of Deferasirox in β-Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State , 2010, Drug Metabolism and Disposition.

[4]  C. Pascutto,et al.  Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study , 2010, Haematologica.

[5]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[6]  R. Hehlmann,et al.  Deferasirox in MDS patients with transfusion-caused iron overload—a phase-II study , 2009, Annals of Hematology.

[7]  D. Steensma,et al.  Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS) , 2008 .

[8]  J. Bennett.  Consensus statement on iron overload in myelodysplastic syndromes , 2008, American journal of hematology.

[9]  J. Ford,et al.  Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen , 2008, Journal of clinical pharmacology.

[10]  M. Cazzola,et al.  Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study , 2007, European journal of haematology.

[11]  P. Armand,et al.  Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. , 2007, Blood.

[12]  H. Cario,et al.  Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. , 2007, Clinical therapeutics.

[13]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Eiskjaer,et al.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.

[15]  Matthew Darlison,et al.  Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.

[16]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[17]  M. Kersten,et al.  Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial , 1996, Annals of Hematology.

[18]  F. Jensen,et al.  The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload , 1996, British journal of haematology.

[19]  U. Germing,et al.  No increase in age-specific incidence of myelodysplastic syndromes. , 2004, Haematologica.